



Curriculum Vitae

Robert Evans Foster, M.D., FACC, FSCAI
Alabama Clinical Therapeutics, LLC
52 Medical Park East Drive, Suite 203
Birmingham, Alabama 35235

Telephone (205) 833-2228
Fax (205) 833-6225

Additional Offices

Birmingham Heart Clinic, P.C.
100 Pilot Medical Drive, Suite 300
Birmingham, Alabama 35235

Hospital Affiliations

St. Vincent's Health Systems Alabama
Birmingham, Trussville, St. Clair, Blount

Education

1986 – 1990	Doctorate of Medicine University of Alabama School of Medicine Birmingham, Alabama
1981 – 1985	Bachelor of Science, Biology Baylor University Waco, Texas

Work Experience

2019 – Present	Investigator, Alabama Clinical Therapeutics, LLC Birmingham, Alabama
2014 – Present	Director, BHC Vein Center Birmingham, Alabama
2013 – 2015	Director, Cardiac Cath Lab, St. Vincent's East Birmingham, Alabama
2012 - Present	Clinical Assistant Professor, University of Alabama at Birmingham Birmingham, Alabama
2010 – 2011	President, Medical Staff, St. Vincent's East Birmingham, Alabama

Work Experience Continued...

2008 – 2010	Vice President, Medical Staff, St. Vincent's East Birmingham, Alabama
1997 - Present	Partner, Birmingham Heart Clinic, P.C. 100 Pilot Medical Drive, Suite 300 Birmingham, Alabama 35235
1996 - 1997	Assistant Professor of Medicine Director, Clinical Cardiovascular MRI Division of Cardiovascular Disease
1993 - 1996	University of Alabama School of Medicine, Birmingham, Alabama Cardiology Fellowship Chairman of the Division of Cardiology: Gerald Pohost, M.D.
1990 - 1993	University of Texas S.W. Health Science Center, Dallas, Texas Post Graduate Training, Internal Medicine Chairman of Medicine: Daniel Foster, M.D.
1987 (summer)	University of Alabama School of Medicine, Birmingham, Alabama. Medical Student Research Fellow Division of Cardiovascular Disease Research Advisor: Gerald M. Pohost, M.D.
1985 - 1986	University of Alabama School of Medicine, Birmingham, Alabama Senior Research Fellow Division of Cardiovascular Disease Research Advisor: Gerald M. Pohost, M.D.

Credentials / Training / Certifications

GCP Training (Site Generated) July 2020
Alabama-Medical License (License #: 17238)
Board Certification- Diplomate- Internal Medicine (1991-2015)
Internal Medicine Recertification (2005-2015)
Diplomate- Cardiovascular Disease (1997-2007)
Recertification- Cardiovascular Disease (2007-2017)
Recertification- Cardiovascular Disease (2017-2027)
Diplomate- Interventional Cardiology (2000-2020)
Diplomate- Nuclear Cardiology (2008-2018)
Certification- Registered Physician in Vascular Interpretation (RPVI)
Certification- Coronary and Peripheral Laser Atherectomy
Certification- Foxhollow Atherectomy
Certification- Carotid Stenting
Diplomate- Venous & Lymphatic Medicine (ABVLM) (2013- present)
Clinical Faculty- Alabama College of Osteopathic Medicine
Certification- Endologix PEVAR

Committees

2016 - Present	Board Member, St. Vincent's CV Line
2009 - 2010	President, Medical Staff St. Vincent's East, Birmingham, AL
2008 - 2009	Chairman, Credentialing Committee, St. Vincent's East, Birmingham, AL
2003 - 2005	Chairman, Cardiovascular Committee Medical Center East, Birmingham, AL

Teaching

2015 – Present	Trainer, Endologix PEVAR
2014 – Present	Trainer, Medtronic Endovenous
2011 – 2014	Trainer, ev3, Inc. SilverHawk® Plaque Excision System
2010 – 2014	Trainer, Cardiovascular Systems Incorporated Diamondback 360®
2009 – 2014	Trainer, Spectranetics Excimer Laser System
1995 – 1997	Introduction to Clinical Medicine (UAB)
1991 – 1993	Introduction to Clinical Medicine (UT Southwestern)

Professional Societies

Founding Member, Society for Cardiovascular Magnetic Resonance (SCMR)
Fellow, American College of Cardiology (FACC)
Society of Cardiac Computed Tomography (SCCT)
American Heart Association (AHA)
Birmingham Cardiovascular Society
American Society of Nuclear Cardiology
Member, American College of Phlebology

Awards & Honors

John S. Miller Award for Outstanding Performance as a House Officer
Department of Medicine, UT Southwestern Medical School Affiliated
Hospitals, Dallas, Texas

First place: 23rd Annual Medical Student Research Competition (1986)

Finalist: 24th Annual Medical Student Research Competition (1987)

Abstracts

1. **Foster R E**, Reeves R C, Canby R C, Evanochko W T and Pohost G M: Proton relaxation time alterations in closed-chest canine models with acute myocardial infarction. Book of Abstracts Fifth Annual Meeting of the Society of Magnetic Resonance in Medicine 1986;2:400-401.
2. **Foster R E**, Canby R C, Shin J, Elgavish G A, and Pohost G M: Sodium-23 NMR prediction of reversibility of function following hypoxia in the isolated perfused rat heart. J Am Coll Cardiol 1987;9:72A.
3. Canby R C, Evanochko W T, Barrett L V, **Foster, R E**, Reeves R C, and Pohost, G M: Demonstration of cardiac allograft rejection in rats using in vivo P-31 spectroscopy. J Am Coll Cardiol, 1986; 7:202A.

Abstracts Continued...

4. Evanochko, W T, Canby R C, Kirklin J K, McGiffin D C, Barrett, L V , Reeves R C, **Foster R E**, and Pohost G M: In vivo P-31 NMR spectroscopic prediction of cardiac allograft rejection. Book of Abstracts Fifth Annual Meeting of the Society of Magnetic Resonance in Medicine, 1986; 3:616-617.
5. **Foster, R E**, and Pohost G M: Sodium-23 NMR prediction of reversibility of function following hypoxia and ischemia in the isolated perfused rat heart. First place in the 23th Annual Medical Student Research Competition, 1986.
6. Reeves, R C, Canby R C, Evanochko W T, **Foster R E**, and Pohost G M: T₁ and T₂ changes with severe flow reduction at 24 and 72 hours after coronary occlusion in dogs. J Am Coll Cardiol, 1987; 9:74A.
7. Canby R C, **Foster R E**, Shin J, Elgavish G A, and Pohost G M: Sodium-23 prediction of reversibility of function following ischemia in the isolated perfused rat heart. Clinical Coll Cardiol, 1987; 35(3):265A.
8. Elgavish G A, **Foster R E**, Canby R C, and Pohost G M: Prediction of reversibility of function in the hypoxic and ischemic isolated perfused rat heart using sodium-23 and phosphorus-31 NMR. Society of Magnetic Resonance in Medicine, 6th Annual Scientific Programs, 1987; 512.
9. **Foster R E**, and Pohost G M: Sodium-23 NMR assessment of the protective effects of reduced temperature following 60 minutes of hypoxia in the isolated perfused rat heart. Finalist in the 24th Annual Medical Student Research Competition, 1987.
10. Johnson D B, **Foster R E**, Perry G J, Blackwell G G, Barilla F, Roney M, Orr R A, Stanley A W H, Pohost G M, Dell'Italia, L J: Angiotensin converting enzyme inhibitor therapy promotes remodeling in patients with left ventricular ejection fraction >40% after acute transmural myocardial infarction. J Am Coll Cardiol, 1996; 27 (2) Suppl A: 200A.
11. Doyle M, **Foster R E**, Pohost G M: Common K-space acquisition: a method to prolong myocardial contrast. Society of Magnetic Resonance in Medicine Book of Abstracts, 1996.
12. Doyle M, **Foster R E**, Pohost G M: Common K-space acquisition: a method to prolong myocardial contrast. Society of Magnetic Resonance in Medicine Book of Abstracts, 1996.
13. Doyle M, Walsh E G, **Foster R E**, and Pohost G M: Rapid high resolution multiple slice imaging with BRISK. Society of Magnetic Resonance in Medicine Book of Abstracts, 1996.
14. **Foster R E**, Johnson D B, Barilla F, Kirk K, Blackwell G G, Roney M, Dell'Italia L J: Effects of low versus titrated dose Ramipril on left ventricular remodeling in patients after Q-wave myocardial infarction with asymptomatic left ventricular dysfunction. Circulation, 94 (8): I-189.

Publications

1. Canby R C, Evanochko W T, Kirklin J K, McGiffin D C, Barrett L V, Sakai T T, Brown M E, **Foster R E**, and Pohost G M: Monitoring the bioenergetic of cardiac allograft rejection using in vivo P-31 NMR spectroscopy. J Am Coll Cardiol, 1986; 9(5):1067-1074.
2. Johnson D B, **Foster R E**, Barilla F, Blackwell G G, Roney M, Stanley A W H, Orr R A, van der Geest R J, Reiber J H C, and Dell'Italia L J: Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction >40% after acute myocardial infarction. J Am Coll Cardiol 1997; 29:49-54.

Publications Continued...

3. Doyle M D, Walsh E G, **Foster R E**, and Pohost G M: Rapid cardiac imaging with Turbo BRISK. *Mag Reson Med* 1996; 410-417.
4. **Foster R E**, Johnson D B, Barilla F, Firk K, Blackwell G G, Orr R, Roney M, and Stanley A W, Pohost G M, and Dell'Italia L J: Effect of angiotensin-converting enzyme inhibitor therapy on left ventricular mass and volumes in patients with left ventricular dysfunction after a Q-wave myocardial infarction. Submitted to *AJC*, 1997.
5. Castro P F, Bourge R C, **Foster R E**. Evaluation of Hibernating Myocardium in Patients with Ischemic Heart Disease. *Am J Med* 1998; 104:69-77.

Book Chapters

Foster, RE and Pohost G M: Magnetic Resonance Imaging of the Heart and Great Vessels. *Hurst's The Heart*. Schlant et al (ed) 1997.

Research Experience

1. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
2. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
3. Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy
4. Stenting of the Superficial Femoral and Proximal Popliteal Arteries With the Boston Scientific INNOVA Self-Expanding Bare Metal Stent System
5. Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis
6. NAC-MD-01 Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
7. Xience V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study
8. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subject with Coronary Artery Disease.
9. A Clinical Evaluation of the Medtronic Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25mm to 4.2mm
10. Phase 3 Randomized Evaluation of the Safety and Efficacy of Apixaban in Patients with a Recent Acute Coronary Syndrome
11. A Randomized, Double-Blind, Double Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events including Bleeding and Symptomatic Ulcer Disease

Research Experience Continued...


12. A Clinical Evaluation of the XIENCE PRIME and XIENCE PRIME LL Everolimus Eluting Coronary Stent System
13. Carotid Stenting for High Surgical Risk Patients: Evaluating Outcomes Through The Collection of Clinical Evidence
14. Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (Registry)
15. Herculink Cobalt Chromium Renal Stent Trial to Demonstrate Efficacy and Safety of the RX Herculink® Elite™ Renal Stent System
16. A Prospective Evaluation in a Randomized Trial of Safety and Efficacy of the Use of the TAXUS® Element TM Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions
17. A Prospective Evaluation in a Non-Randomized Trial of Safety and Efficacy of the Use of the TAXUS® Element TM Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels
18. A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalvular Atrial Fibrillation
19. A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg or Placebo When Co-administered with Statins in Subjects with Hypercholesterolemia, With an Optional Open-Label Extension
20. A Randomized, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patient With Non-ST or ST Elevation Acute Coronary Syndromes (ACS). [PLATO-A Study Of Platelet Inhibition and Patient Outcomes].
21. Carotid RX ACCULINK/RXACCUNET Post-Approval Trial to Uncover Unanticipated and Rare Events
22. D.E.S.cover Registry
23. A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention
24. A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedaron 400mg bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients with Atrial Fibrillation/Atrial Flutter (AF/AFL)
25. A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/ Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting with Acute Coronary Syndrome
26. A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG™ MR) and Atenolol in Combination with and Compared to an Angiotensin Converting enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (LVH).

Research Experience Continued...

27. Saphenous Vein Graft Protection In a Distal Embolic Protection Trial
28. A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems
29. A 12-week, Randomized, Open-label, 3-Arm, Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of Atorvastatin 80 mg in Subjects with Acute Coronary Syndromes/AstraZeneca.
30. Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events/ Medicines Co.
31. A Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects with Coronary Artery Disease Using Intravascular Ultrasound (IVUS)/Sankyo
32. A Double-Blind, Randomized, Multicenter, Dose-Ranging Trial of CS-747 Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention/Brigham and Women's Hospital.
33. A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Extended Release Metoprolol Succinate (Toprol-XL on Cardiac Remodeling in Asymptomatic Patients (NYHA Class 1) with Left Ventricular Dysfunction/AstraZeneca.
34. A 6-week, Open-label, Dose-comparison Study to Evaluate the Safety and Efficacy of ZD4522 vs. Atorvastatin, Cerivastatin, Pravastatin, and Simvastatin in Subjects With Hypercholesterolemia/ AstraZeneca.
35. Protocol M100240/ 2004/ Aventis.
36. A Prospective, Non-Randomized, Multi-Center, Single-Arm Clinical Trial to Assess the Safety and Efficacy of the RX Herculink 14 Peripheral Stent System for Treatment of Sub-Optimal Post-Procedural Percutaneous Transluminal Angioplasty (PTA) Results in De Novo or Restenotic Renal Artery Stenoses/ Guidant.
37. Protocol 579/ Mayo Physician Alliance for Clinical Trials.
38. Clinical Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Eplerenone in Patients with Heart Failure Following Acute Myocardial Infarction/ Pharmacia.
39. A Randomized, Double-Blind, Active-Controlled Evaluation of the Antihypertensive Response to Omapatrilat in Subjects Uncontrolled on Ace Inhibitor Monotherapy/ Bristol-Myers Squibb.
40. A Double-blind, Randomized Comparison Study of the Safety and Efficacy of Pioglitazone HCL or Glyburide in Subjects with Type II Diabetes Mellitus Post Acute Myocardial Infarction and/or Percutaneous Coronary Intervention/Takeda Pharmaceuticals.
41. A Prospective, Open-label, Randomized, Parallel-group Investigation to Evaluate the Efficacy and Safety of Enoxaparin vs Unfractionated Heparin in Subjects Who Present to the Emergency Department with Acute Coronary Syndrome/ Aventis.
42. A Phase 3, Randomized, Double-blind, Placebo-controlled study to Evaluate Pemfibrate's ability to Reduce cardiovascular outcomes by reducing triglycerides in patients with Diabetes.

A handwritten signature in black ink, appearing to read 'R. E. Foster', written over a horizontal line.

Robert Evans Foster, M.D., FACC, FSCAI

A handwritten date '8-26-2020' in black ink, written above a horizontal line.

Date